Stocktoria
AMGEN INC AMGN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1983-06-17
AMGEN INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 24.7% | 21.7% | 28.0% | 36.3% | 29.4% |
| Net margin | 21.0% | 12.2% | 23.8% | 24.9% | 22.7% |
| FCF margin | 22.0% | 31.1% | 26.1% | 33.4% | 32.3% |
| Return on assets | 8.5% | 4.5% | 6.9% | 10.1% | 9.6% |
| Return on equity | 89.1% | 69.6% | 107.8% | 179.0% | 88.0% |
| Debt / equity | 6.31× | 10.23× | 10.37× | 10.64× | 4.97× |
| Current ratio | 1.14 | 1.26 | 1.65 | 1.41 | 1.59 |
| Revenue growth | 10.0% | 18.6% | 7.1% | 1.3% | 2.2% |
Source: SEC EDGAR filings · CIK 0000318154 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.